TARGETED AND UNTARGETED FUSION PROTEINS: CURRENT APPROACHES TO CANCER IMMUNOTHERAPY - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 301

21. Sutmuller RP, van Duivenvoorde LM, van Elsas A,
Schumacher TNM, Manon E. Wildenberg ME, et al.
(2001) Synergism of cytotoxic T lymphocyte-associated
antigen-4 blockade and depletion of CD25 þ regulatory
T cells in antitumor therapy reveals alternative pathways
for suppression of autoreactive cytotoxic T lymphocyte
responses. J. Exp. Med. 194, 823-832.
22. Munn DH, Mellor AL. (2004) IDO and tolerance to tumors.
Trends Mol. Med. 10, 15-18.
23. Parmiani G, Rivoltini L, Andreoda G, Carrabba M. (2000)
Cytokines in cancer therapy. Immunol. Lett. 74, 41-44.
24. Ben-Efraim S. (1999) One hundred years of cancer immuno-
therapy: a critical appraisal. Tumor Biol. 20, 1-24.
25. Bubenik J, Otter W, Huland E. (2000) Local cytokine therapy
of cancer: interleukin-2, interferon, and related cytokines.
Cancer Immunol. Immunother. 49, 116-122.
26. Di Cailo E, Forni G, Lollini P, Colombo MP, Modesti A,
Musiani P. (2001) The intriguing role of polymorphonuclear
neutrophils in anti-tumor reaction. Blood 97, 339-345.
27. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. (1998)
Infarction of solid Hodgkin's tumors in mice by antibody-
directed targeting of tissue factor to tumor vasculature.
Cancer Res. 58, 4646-4653.
28. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. (2003)
Comparison of three different targeted tissue factor fusion
proteins for inducing tumor vessel thrombosis. Cancer Res.
63, 5046-5053.
29. Dowell RI, Springer CJ, Davies DH, Hadley EM, Philip J,
Burke PJ, et al. (1996) New mustard prodrugs for antibody-
directed enzyme prodrug therapy: alternatives to the amide
link. J. Med. Chem. 39, 1100-1105.
30. Haisma HJ, Brakenhoff RH, van der Muelen-Muileman IH,
Boven E. (1998) Construction and characterization of a
fusion protein of single chain anti-carcinoma antibody
323/A3 and human b -glucuronidase. Cancer Immunol.
Immunother. 45, 266-272.
31. Schmidt SR. (2009) Fusion proteins as biopharmaceuticals—
applications and challenges. Curr. Opin. Drug Discov. Devel.
12, 284-295.
32. Schrama D, Reisfeld RA, Becker JC. (2006) Antibody tar-
geted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5,
147-159.
33. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML.
(2008) Antibody-cytokine fusion proteins: applications in
cancer therapy. Expert Opin. Biol. Ther. 8, 609-632.
34. Epstein AL, Chen FM, Taylor CR. (1988) A novel method for
the detection of necrotic lesions in human cancers. Cancer
Res. 48, 5842-5848.
35. Chen FM, Hansen EB, Taylor CR, Epstein AL. (1991)
Diffusion and binding of monoclonal antibody TNT-1 in
multicellular tumor spheroids. J. Natl. Cancer Inst. 83,
200-204.
36. Miller GK, Naeve GS, Gaffar SA, Epstein AL. (1993)
Immunologic and biochemical analysis of TNT-1 and
TNT-2 monoclonal antibody binding to histones. Hybridoma
12, 689-698.

37. Epstein AL, Chen D, Ansari A, Najafi A, Siegel M, Lee K,
et al. (1991) Radioimmunodetection of necrotic lesions in
human tumors using I-131 labeled TNT-1 F(ab') 2 monoclonal
antibody. Antibody Immunoconj. Radiopharm. 4, 151-161.
38. Hornick JL, Hu P, Khawli LA, Hu P, Biela BH, Mizokami
MM, et al. (1998) A new chemically modified chimeric
TNT-3 monoclonal antibody directed against DNA for
the radioimmunotherapy of solid tumors. Cancer Biother.
Radiopharm. 13, 255-268.
39. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, et al. (2005)
Pivotal study of iodine-131-labeled chimeric tumor necrosis
treatment radioimmunotherapy in patients with advanced
lung cancer. J. Clin. Oncol. 23, 1538-1547.
40. Yu L, Ju D, Chen W, Li T, Xu Z, Jiang C, et al. (2006) I-131
chTNT radioimmunotherapy of 43 patients with advanced
lung cancer. Cancer Biother. Radiopharm. 21, 5-14.
41. Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA,
LeFleur DW, et al. (2000) Tumor rejection and immune
memory elicited by locally released LEC chemokine are
associated with and impressive recruitment of APCs, lym-
phocytes, and granulocytes. J. Immunol. 164, 3200-3206.
42. Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P,
Veglia F, et al. (1999) Induction of therapeutic T-cell
immunity by tumor targeting with soluble recombinant B7-
immunoglobulin costimulatory molecules. Cancer Res. 59,
2650-2656.
43. Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N,
et al. (2001) Induction of autitumor immunity via intratu-
moral tetra-costimulator protein transfer. Cancer Res. 61,
8127-8134.
44. Yamaguchi N, Hiraoka SI, Mukai T, Takeuchi N, Zhou XY,
Ono S, et al. (2004) Induction of tumor regression by
administration of B7-Ig fusion proteins: mediation by type
2 CD8 þ T-cells and dependence on IL-4 production.
J. Immunol. 172, 1347-1354.
45. Smith KA. (1993) Lowest dose interleukin-2 immunotherapy.
Blood 81: 1414-1423.
46. Silagi S, Shaefer A. (1986) Successful immunotherapy of
mouse melanoma and sarcoma with rIL-2 and cyclophospha-
mide. J. Biol. Response Modif. 5, 411-422.
47. Sone S, Ogura T. (1994) Local interleukin-2 therapy for
cancer, and its effect induction mechanisms. Oncology 51,
170-176.
48. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Bishan S.
Charak BS, et al. (1991) Enhanced tumor uptake of
macromolecules induced by a novel vasoactive interleukin-
2 immunoconjugate. Cancer Res. 51, 2694-2698.
49. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA.
(1998) Immunocytokines: a promising approach to cancer
immunotherapy. Pharmacol. Ther. 80, 277-292.
50. Khawli LA,Miller GK, EpsteinAL. (1994) Effect of seven new
vasoactive immunoconjugates on the enhancement of mono-
clonal antibody uptake in tumors. Cancer S73, 824-831.
51. Khawli LA, Hornick JL, Sharifi J, Epstein AL. (1997)
Improving the chemotherapeutic index of IUdR using a
vasoactive immunoconjugate. Radiochim. Acta 79, 83-86.